Affordable Access

deepdyve-link
Publisher Website

Cost-effectiveness of omalizumab for the treatment of inadequately controlled severe allergic asthma in Chinese children.

Authors
  • Zhou, Hua1
  • Lu, Yanming2
  • Wu, Bin3
  • Che, Datian1
  • 1 Department of VIP, Shanghai Children's Hospital, affiliated with the School of Medicine, Shanghai Jiaotong University, Shanghai, China. , (China)
  • 2 Department of Pediatrics, Ren Ji Hospital, South Campus, School of Medicine, Shanghai Jiaotong University, Shanghai, China. , (China)
  • 3 Medical decision and Economic Group, Department of Pharmacy, Ren Ji Hospital, South Campus, School of Medicine, Shanghai Jiaotong University, Shanghai, China. , (China)
Type
Published Article
Journal
Journal of Asthma
Publisher
Informa UK (Taylor & Francis)
Publication Date
Jan 01, 2020
Volume
57
Issue
1
Pages
87–94
Identifiers
DOI: 10.1080/02770903.2018.1544642
PMID: 30507328
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

Objective: The addition of omalizumab to standard therapy has proven to be efficacious in children with severe allergic asthma. The goal of this study was to assess the cost-effectiveness of adding omalizumab to standard treatment for asthma in Chinese pediatric patients.Methods: A Markov model was constructed to project the health and economic outcomes in pediatric patients with severe allergic asthma. Model inputs were obtained from the literature. Cost and quality-adjusted life-years (QALYs) were measured over a five-year time horizon. One-way and probabilistic sensitivity analyses were conducted.Results: For the base-case analysis, the addition of omalizumab to standard therapy yielded an incremental cost of $49,047 for 0.232 incremental QALY, led to an incremental cost-effectiveness ratio of $211,217/QALY. Sensitivity analyses were robust for these results.Conclusions: This study found that the addition of omalizumab is not a cost-effective strategy compared with standard therapy for children with severe allergic asthma in China due to its high cost.

Report this publication

Statistics

Seen <100 times